Compare AbCellera Biologics Inc (ABCL) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

SPXL, a leveraged ETF tracking the S&P 500, trades at $275.77, up 2.62% with strong bullish technical signals from moving averages. Recent sector rotation has pressured tech stocks, though broader market optimism persists. The fund's performance is tied to daily S&P 500 returns, with a dividend scheduled for June 2026.

Outlook remains tied to S&P 500 momentum, with potential for gains if earnings meet high expectations, but risks include volatility decay from daily rebalancing and market corrections. Investors should weigh the ETF's leverage against broader economic indicators and sector performance.